Autologous and allogeneic transplantation are increasingly used in the management of patients with chronic lymphocytic leukemia. Many questions regarding patient selection, efficacy and outcome are unresolved, hence a review of the literature through Medline search. Autologous transplantation for CLL has been used mainly in selected patients under the age of 60.
Introduction
Chronic lymphocytic leukemia (CLL) accounts for approximately 25-30% of all leukemias occurring in the Western hemisphere. It is a disease characterized by marked heterogeneity in clinical behavior and in life expectancy for those affected by it. Although generally considered a disease of the elderly, it is increasingly recognized in younger patients; management of these younger patients poses peculiar challenges.
Treatment options for CLL used to consist of treatment with steroids, alkylating agents or observation. In the past decade a number of new medical treatments have been developed, many with promising response rates, but none yet with realistic curative potential. 1, 2 Autologous and allogeneic transplantation, the topics of this review, while less widely applicable, induce very high remission rates and a small percentage of durable remissions and are appealing strategies for younger patients. 3 In the future, it is likely that more effective induction treatments will be combined with or followed by transplantation in order to achieve durable remissions in increasing numbers of patients.
High-dose chemotherapy and autologous transplantation for CLL
Autologous transplantation is based on the observation that for some chemotherapeutic agents, efficacy is related in a linear fashion to the dose administered, such that increasing the dose of a given drug may result in higher anti-tumor efficacy. 4, 5 Autologous transplantation is a logical approach in CLL given prior evidence that dose intensification results in increased response rates in patients with CLL. 6 Over the past decade numerous studies of autologous transplantation have been reported. They are summarized in Table 1 and four studies published in peer reviewed journals are discussed below.
In 1993, Rabinowe et al 7 were the first to report a series of 12 patients with CLL who underwent autologous transplantation. All patients had unfavorable prognostic features, but had chemotherapy-sensitive disease. Despite extensive pretransplant chemotherapy, only two of the 12 patients were in clinical CR before BMT; all others had residual disease in the bone marrow (up to 10% bone marrow involvement) and/or lymph nodes. The bone marrow was purged with a cocktail of anti-B cell monoclonal antibodies (anti-CD20, B5 and anti-CD10), and the conditioning regimen consisted of cyclophosphamide 120 mg/kg and TBI 2 Gy twice a day ×7 doses. Ten of the 12 patients obtained a complete remission after transplantation. Follow-up testing of the bone marrow including dual-color immunofluorescence and Southern blot showed absence of detectable CLL. In three cases with follow-up beyond 1 year, no recurrence could be detected. Other indicators of residual disease such as hypogammaglobulinemia and cytogenetic abnormalities commonly reverted to normal. At 12 months the predicted disease-free survival for the whole cohort was 82% (95% CI 64-100%). More recently, the same group presented a follow-up report on 81 patients. 8 Eight patients died from treatment-related causes. With a median follow-up of 30 months, disease-free survival is estimated at 63% at 4 years, and overall survival is estimated at 85%. In a second study, Khouri et al, 9 from MD Anderson, reported 11 patients with advanced CLL ( median age 47.5 years) who underwent autologous transplantation. Bone marrow was harvested when the biopsy showed less than 15% malignant cells. The marrow of seven of the patients was purged with an anti-B cell monoclonal antibody, prior to transplantation. 10 All patients obtained major responses -six patients achieved CR, four had a nodular CR and one had a partial remission. Three patients relapsed with Richter's transformation at 4, 6 and 8 months and two patients relapsed with CLL 12 and 15 months post BMT. Two additional patients died from complications, one CMV pneumonia and one from complications after liver biopsy. Only four patients continued to be in partial (one) or complete (three) remission 2 months, 4 months, 5 months and 29 months after transplantation. The high rate of early recurrences in this study contrasts with the results from (12), CyTBI Ara-C (one) or BEAC (three). Unpurged marrow or stem cells were used in three and 13 patients, respectively. Only three patients were in CR at the time of transplantation. All patients achieved a remission and absence of disease detectable by dual-color immunofluorescence. Five patients remained in complete remission at 22, 27, 48, 60 and 125 months after transplantation.
In addition to these published series, a number of retrospective analyses of larger patient groups have been reported in abstract form. [13] [14] [15] [16] [17] The results of these studies are included in Table 1 . Transplant-related mortality is fairly consistently reported in the 10% range. Complete remissions are commonly observed, but there is also a fairly high recurrence rate. 12, 13, 15 On the other hand, very prolonged remissions occur in a small fraction of the patients. 12 Those prolonged remissions can serve as a 'proof of principle' of the potential impact of autologous transplantation in CLL. In order to improve the results and better define the role of transplantation in the management of CLL, a number of important issues, relating to stem cell source and purging, conditioning, pre-and post-transplant chemotherapy and patient selection are to be studied.
Stem cells or bone marrow? Purging?
Bone marrow stem cells were used for the initial transplant studies in CLL. Peripheral blood stem cell transplantation has advantages relating to ease of collection and rapidity of hematopoietic reconstitution and is increasingly used. Residual disease in the stem cell infusate or in blood and bone marrow post transplant can be detected by various methods, such as measurement of kappa/lambda ratios, dual-or tri-color immunofluorescence (eg CD5/CD19), Southern blot or PCR-based methods. Of these methods, PCR of the IgH gene rearrangement has the highest sensitivity and has most closely been correlated with risk for clinical recurrence. Utilizing any of these methods, involvement of bone marrow and/or peripheral blood can almost uniformly be detected at the time of harvest in patients with CLL treated with conventional chemotherapies. Collection of bone marrow and or stem cells thus entails the risk of collection of malignant, potentially clonogenic cells that may contribute to disease recurrence as has been shown in acute leukemia and chronic myelogenous leukemia, 18, 19 and suggested in follicle center and mantle cell Leukemia lymphoma. 20, 21 Many centers have used stem cell purging to eliminate such contaminating cells. Unfortunately, current purging methods, based on negative selection with anti-B cell antibodies or on positive selection with anti-CD34 antibodies are only moderately effective. For example, in the DanaFarber experience, residual disease remained detectable in the marrow after purging with a cocktail of three anti-B cell antibodies in 11 of 21 patients. 22 The MD Anderson group found residual clonal cells by dual-color immunofluorescence in five of seven marrows subjected to B cell depletion. 9 Dreger et al 23 employed either positive selection (CD34 enrichment) of peripheral blood stem cells or negative selection (B cell depletion) of bone marrow. They found complete elimination of immunofluorescence detectable cells in nine of 11 products thus treated. However, PCR negativity was achieved in only three cases. The same German group is currently investigating the use of combined positive-negative selection based on the concern that in at least some cases of CLL, CD34-positive leukemia precursors are present. [24] [25] [26] After using this technique, CLL cells could be detected in the peripheral blood progenitor collection by PCR in only 15/25 products, probably the best results reported until now. 27, 28 In vivo purging, the achievement of molecular remission through pre-transplant treatment is also increasingly being considered. In follicular lymphoma, treatment with rituximab (a humanized anti-B cell antibody) and intensive chemotherapy results in molecular remissions and has allowed the collection of tumor-free grafts. 29 In CLL, increasingly effective chemotherapy regimens or campath-1H, (a humanized monoclonal directed against CD52 which is abundantly expressed on CLL cells), result in higher remission rates than was previously possible. [30] [31] [32] [33] With combinations of chemotherapy and rituximab or campath-1H, molecular remissions are obtained in a proportion of patients who then might be considered for consolidation with autologous transplantation. 34, 35 Although in vitro and or in vivo purging is a logical approach and the subject of much research, its importance in CLL autotransplantation is not entirely clear. Paradoxically, even when tumor-containing stem cells are infused during the autotransplant, molecular remissions (ie absence of PCR detectable CLL cells in bone marrow and blood) are often obtained after transplantation. This is in contrast to low grade lymphoma and mantle cell lymphoma where infusion of tumor-contaminated cells is closely related to disease recurrence. 20, 21 It is more akin to observations in multiple myeloma, 36 and suggests that in some cases the remaining CLL cells contained in the bone marrow harvest, no longer have proliferative potential. When minimal residual disease is found after transplantation and monitored longitudinally, several patterns are observed. 22 (Table 2) . In some patients, there is a rapid disappearance of PCR-detectable CLL cells after transplant. Those patients are at low risk for recurrence. If recurrence occurs, it may be preceded by the reappearance of PCR-detectable disease. In a second group of patients, CLL can be detected immediately after transplant, but there is a gradual disappearance of PCR-detectable cells within the first 3 to 12 months after transplantation. Again, such patients appear to be at relatively low risk of disease recurrence. The transient PCR positivity may result from the infusion of CLL cells contained in the stem cell product that are not clonogenic. In a third group of patients, PCR-detectable cells remain present at every sampling point after transplantation. This group of patients almost invariably relapse. Finally, in some patients, PCR-detectable cells have reoccurred after a prolonged period of PCR negativity. Some, but not all of these patients have developed clinical recurrences. More recently, semi-quantitative PCR analysis has been used. 37 Increasing levels of residual disease, as detected by this test, may be a better predictor of the risk for disease recurrence.
Conditioning for autologous transplantation
The conditioning for autologous transplantation has almost always consisted of TBI-containing regimens. The experience with non-TBI regimens is increasing, but in at least one analysis the use of TBI regimens was associated with a significantly improved outcome. 15 The impact of different conditioning regimens will need to be studied prospectively in order to clearly establish their role.
Lead time bias and patient selection
Most reported outcomes of autologous transplantation are influenced by patient selection and lead time bias. A few prospective studies have addressed these issues by accounting for high rates of patient drop-out during induction chemotherapy prior to transplantation. For example, Dreger and Schmitz 38 reported 18 patients with recurrent or newly diagnosed CLL, who received one to two cycles of dexaBEAM followed by B cell-depleted stem cell or bone marrow harvest. Only 13 of the 18 patients subsequently underwent autologous transplantation. In a more recent report, they used CHOP or fludarabine for induction of remission and obtained responses in 53 out of 65 patients. 39 Sutton et al 40 reported 20 patients with recurrent or refractory CLL who were enrolled on a prospective study of ESHAP induction chemotherapy, followed by autologous transplantation for those with responsive disease. A TBI-containing conditioning regimen was used. An adequate response to ESHAP was obtained in 13 patients (five failed to respond and two died from chemotherapy-related complications). Of these 13, bone marrow collection or PBSC mobilization was attempted in 12 patients and was successful in eight patients. Five patients underwent bone marrow transplantation and three underwent stem cell transplantation. 41 reported on eight patients with CLL who were to undergo autologous transplantation after disease reduction with fludarabine (n = 7) or CHOP (n = 1). In five patients who responded well to fludarabine or CHOP, stem cell collection could easily be achieved. But three nonresponders to fludarabine, also did not mobilize stem cells well and could not be transplanted.
Finally, Ittala et al

Fludarabine and stem cell mobilization
Inability to mobilize stem cells or collect bone marrow is a common problem in patients with CLL that may derive from heavy bone marrow involvement in some patients and from stem cell damage in others. 40 In this respect, treatment with fludarabine or 2CDA, or extensive prior treatment with alkylating agents, 42 may affect the ability to mobilize stem cells.
Fludarabine, in particular, is widely used in the treatment of CLL and its effect on stem cells or the ability to mobilize stem cells is controversial. Ittala et al 41 and Sala et al 43 suggest that treatment with fludarabine, by inducing responses, may restore the bone marrow compartment of hematopoietic progenitors. Michallet et al 44 also reported data on 29 patients with CLL, previously treated with fludarabine, who underwent PBSC mobilization at different European centers. They also found that receiving more than six courses of fludarabine was associated with better mobilization (P = 0.03); but a delay of more than 2 months between the last course of fludarabine and stem cell mobilization was strongly associated with better stem cell yield (P = 0.0001). By contrast, Visani et al, studying acute leukemia patients and Ketterer et al, who reported on patients with lymphoid malignancies, reported a strong association between prior exposure to fludarabine and poor stem cell yields. 45 , 46 Visani et al also reported that those patients who were successfully mobilized had delayed platelet recovery after autologous stem cell transplantation. Finally, Flinn et al 31 reported on 20 patients with previously untreated lymphoid malignancies who underwent autologous transplantation after induction therapy with cyclophosphamide and fludarabine. Engraftment was prompt in the majority of patients, but one patient died of graft failure. Although additional study is needed, it appears likely that fludarabine affects the 'mobilizable' stem cell compartment and may in some cases have an adverse effect on stem cell mobilization. This effect may be related to timing and dose of the drug and may be counterbalanced by its antitumoral efficacy that results in restoration of bone marrow space. Fludarabine has been the most active chemotherapeutic agent in the management of CLL and is likely to be used in the majority of patients. Prospective studies are needed to address the issues of proper timing and sequencing of fludarabine treatment vs high-dose chemotherapy in a comprehensive management plan for CLL.
Future studies
Given the requirements for disease response, ability to collect progenitor cells, and reasonable performance status, selection of patients with favorable characteristics and lead time bias is certain to have played a role in the reported results of autologous transplantation. Nevertheless, the procedure has clearly benefited selected patients. Large randomized studies are needed to establish the role of autologous transplantation in overall patient management. Such studies are ongoing in Europe and have been proposed in the US. [47] [48] [49] [50] Further improvements in conditioning therapy, in stem cell engineering, preand/or post-transplant therapy also requires further investigation.
Allogeneic transplantation
The use of tumor-free grafts constitutes an obvious advantage of allogeneic over autologous stem cells. The contribution of graft-versus-leukemia effects on tumor control, on the other hand, depends on technical factors related to transplantation, (ie the conditioning, the graft composition and the GVHD prophylaxis regimen) but also on the underlying disease. The strongest evidence for GVL effects in CLL comes from case reports of tumor response upon withdrawal of immunosuppressants or DLI. [51] [52] [53] [54] [55] Others have reported delayed responses, correlating with the achievement of complete chimerism and attributed to GVL. [56] [57] [58] [59] [60] An alternative explanation in such cases could be that the responses are due to ongoing apoptosis of CLL cells that were irreparably damaged by conditioning.
The most informative cases are those where clear-cut disease recurrence or progression occurs after allogeneic transplantation and this is treated by DLI. Very few such cases have been reported. Zelenetz et al 61 report one patient with progressive CLL after matched unrelated donor transplantation, who received rituximab followed by DLI. Six months later, the patient had obtained a complete remission in the blood, but continued to have lymphadenopathy. By contrast, we observed a patient who failed to respond to DLI. This patient had a partial remission after allogeneic transplantation, with persistent minimal marrow involvement. Approximately 2 years after allogeneic transplantation he developed disease progression. Subsequently, he failed to respond to a second allogeneic transplant and to three consecutive infusions of donor lymphocytes from his HLA-identical sibling. He also did not develop any signs of graft-versus-host disease. Retreatment with fludarabine resulted in a transient response, but ultimately the patient died of CLL. This disappointing observation indicates that GVL mechanisms are not uniformly Leukemia effective in CLL. Careful study of larger numbers of patients will be necessary to define their precise role.
Regardless of the mechanism of action, allogeneic transplantation has been effective in selected patients with poor risk disease (Table 3) . Michallet et al 62 reported 54 patients with CLL who underwent allogeneic transplant between 1984 and 1992 in 30 centers and were reported to the EBMTR and the IBMTR. Median age at transplantation was 41 years. Transplant regimens varied, but consisted mostly of cyclophosphamide-TBI. Hematological remission was obtained in 38 patients. Twenty-four patients (44%) were alive with a median follow-up of 27 months (5-80 months) . The 3 year survival probability was 46% (95% CI 32-60%), and was not clearly associated with the stage of disease, but it was associated with disease responsiveness prior to transplantation. Patients with chemotherapy-responsive disease had 86% survival (95% CI 62-100%), those with stable disease at transplant had 61% survival (95% CI 38-84%), and those with progressive disease had only 23% survival (95% CI 2-44%). Twenty-five of the 30 treatment failures were due to treatment-related causes. This publication established the feasibility of allogeneic transplantation, but also highlighted its toxicity and the high treatmentrelated mortality.
The Dana-Farber group has reported a fairly large series of patients undergoing allogeneic transplantation. 7, 8 They used bone marrow grafts treated with anti-CD6, a T cell-depleting agent. Such allogeneic transplants result in minimal GVHD, but also have fewer GVL effects than undepleted transplantation. Their patients undergoing allogeneic transplantation were selected in a similar fashion to the patients undergoing autologous transplantation at Dana-Farber. Recurrence rates after allogeneic transplantation were similar to those in autologous recipients and treatment-related mortality was slightly higher. With more prolonged follow-up, they report a 50% estimated survival rate at 4 years after allogeneic transplantation, which is significantly inferior to survival after autologous transplantation (85% at 4 years, P Ͻ 0.01). 63 Pavletic et al 64 reported 23 patients undergoing allogeneic transplantation after conditioning with TBI-containing regimens. Median follow-up was 26 months and the projected 5 year survival 65% (95% CI 48-88%). Eight of the 23 patients died from treatment-related causes. Several other small studies show similar outcomes. 65, 66 The IBMTR also recently reported in abstract form the outcome of 325 patients undergoing transplantation between 1990 and 1999.
14 Two hundred and forty-two of the patients underwent allografting and 83 underwent autologous transplantation. Consistent with the Dana-Farber results, 3 year survival probability was 45% for those undergoing allogeneic transplantation vs 87% for those undergoing autologous transplantation. Michallet et al, 67 reporting for the European registry (EBMTR), analyzed data on 135 patients undergoing allogeneic transplantation. The response rate was 87%. The estimated 3 year survival was 54% (95% CI 43-65). Treatment-related mortality was 40%.
Khouri et al, 9 from MD Anderson Cancer Center, reported a group of 11 patients including some with refractory CLL. With a median follow-up of appproximately 1 year, 10 of the patients remained alive. Seven were in CR. They speculated that these encouraging results were related to GVL effects. The MD Anderson group also reported a very low incidence of GVHD after allogeneic transplantation, despite the inclusion of older patients. 68 They attributed this to the prior exposure of CLL patients to repeated doses of fludarabine. Consistent with this hypothesis, it has been recently demonstrated in a Further extending their hypothesis that GVL effects are the major determinant of outcome after allogeneic transplantation, Khouri et al 55 have evaluated the use of non-myeloablative conditioning in CLL. Such regimens are based on the immunosuppressive effects of fludarabine or low doses of TBI. Their toxicity is reduced compared with TBI-containing regimens and it is hoped that severe GVHD will also be decreased. Initially they reported a series of 15 patients, where they used different variants of non-myeloablative conditioning. Eleven of 15 patients engrafted, and five of the 11 were alive and in remission at the time of the initial report. Recently, they reported 11 consecutive patients who received conditioning with cyclophosphamide 2250 mg/m 2 and fludarabine 90 mg/m 2 . 70 They compared them with 29 patients undergoing full myeloablative conditioning. With a median follow-up time of 40 months, 3 year survival was 47% (95% CI 33-68). Toxicity was much reduced among those receiving non-myeloablative transplants, but survival was not improved. Other groups are also reporting data on non-myeloablative transplantation. 59, 71, 72 Generally, toxicity is low, engraftment occurs reliably, but there are considerable problems with acute and chronic GVHD and disease recurrence. In none of these reports is there sufficient follow-up to estimate cure rates. The Seattle group also reported on 26 patients with CLL who underwent allogeneic transplantation between 1980 and 1999. 60 In this small series, improved survival was associated with the use of TBI-containing regimen. Five year survival for the seven patients conditioned with Bu-CY was 0% vs 48% for those receiving TBI-based conditioning. These data underscore the need for prolonged follow-up of new treatment modalities and especially of the use of non-myeloablative conditioning in CLL.
Matched sibling donor transplantation is applicable in only 20-30% of potential recipients. In order to extend the donor pool, alternative donor transplantation has been considered. Options include unrelated donor transplantation, cord blood transplantation and haplo-identical transplantation. These types of transplant have been tested mainly in young patients with advanced forms of acute leukemia. Increasingly, longterm survival and disease-free survival are demonstrated. It is conceivable that in the future these technologies will be attempted more in patients with CLL, but to date few such cases have been reported and follow-up has been very limited. 14, 59, 67 Conclusions Autologous transplantation has been tested mainly in younger patients with adverse prognostic features. Stem cell purging has commonly been used, but with most currently used techniques, CLL cells cannot be completely eliminated. Nevertheless, complete clinical and molecular remissions are often obtained after transplantation. The duration of remission may correlate with the attainment of PCR-documented molecular remissions in the blood and/or marrow. The results of autologous transplantation are encouraging enough that several randomized studies of this approach in patients with newly diagnosed disease have been proposed or are ongoing. Given the advances in supportive care, it would also be appropriate to extend this approach to older patients with adverse prognostic features. The lifespan and quality of life of these patients is often considerably reduced by their disease and conventional Leukemia treatments continue to be only marginally effective. In myeloma, a very similar disease, high-dose chemotherapy has made a considerable impact on the quality of life in elderly patients, with minimal morbidity and mortality. 73 Until now, patients have been selected for transplant based on features related to the course of their disease, such as Rai stage, lymphocyte doubling time and response to chemotherapy. Future studies will need to take into account the impact of newly recognized prognostic features that are related to disease biology. These include certain cytogenetic abnormalities, 74 cytokine levels, 75 and more recently CD38 expression or lack of somatic mutations in the immunoglobulin genes. 76 Allogeneic transplantation continues to involve considerable risks. The use of mini-transplants has decreased early toxicity, but it is likely that older patients will continue to be at very high risk for extensive chronic GVHD, a crippling and sometimes fatal condition. Furthermore, it remains to be established what percentage of patients obtain durable complete remissions. We currently recommend allogeneic transplantation only to patients with very high risk disease who are not candidates for autologous transplantation. This mainly involves patients with extensive bone marrow involvement or whose stem cells cannot be mobilized. We continue to recommend TBI-based conditioning for those who can tolerate it. Future efforts in allogeneic transplantation should be directed at reducing the risk for chronic GVHD, while devising strategies to maintain disease control.
